AR043629A1 - Derivados cuaternarios de quelidonina - Google Patents
Derivados cuaternarios de quelidoninaInfo
- Publication number
- AR043629A1 AR043629A1 ARP040100877A ARP040100877A AR043629A1 AR 043629 A1 AR043629 A1 AR 043629A1 AR P040100877 A ARP040100877 A AR P040100877A AR P040100877 A ARP040100877 A AR P040100877A AR 043629 A1 AR043629 A1 AR 043629A1
- Authority
- AR
- Argentina
- Prior art keywords
- reaction
- quaternary
- quelidonine
- hydrogen
- alkylating agent
- Prior art date
Links
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 3
- 229930013930 alkaloid Natural products 0.000 abstract 2
- 150000003797 alkaloid derivatives Chemical class 0.000 abstract 2
- 229940100198 alkylating agent Drugs 0.000 abstract 2
- 239000002168 alkylating agent Substances 0.000 abstract 2
- 239000007795 chemical reaction product Substances 0.000 abstract 2
- 229910052739 hydrogen Inorganic materials 0.000 abstract 2
- 239000001257 hydrogen Substances 0.000 abstract 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 abstract 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- FOCVUCIESVLUNU-UHFFFAOYSA-N Thiotepa Chemical compound C1CN1P(N1CC1)(=S)N1CC1 FOCVUCIESVLUNU-UHFFFAOYSA-N 0.000 abstract 1
- 238000010306 acid treatment Methods 0.000 abstract 1
- 239000003125 aqueous solvent Substances 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- GHKISGDRQRSCII-ZOCIIQOWSA-N chelidonine Chemical class C1=C2[C@H]3N(C)CC4=C(OCO5)C5=CC=C4[C@H]3[C@@H](O)CC2=CC2=C1OCO2 GHKISGDRQRSCII-ZOCIIQOWSA-N 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 abstract 1
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 1
- 230000036737 immune function Effects 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 230000003818 metabolic dysfunction Effects 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 239000000047 product Substances 0.000 abstract 1
- 230000000069 prophylactic effect Effects 0.000 abstract 1
- 239000011541 reaction mixture Substances 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
- 229960001196 thiotepa Drugs 0.000 abstract 1
- 238000005406 washing Methods 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/14—Quaternary ammonium compounds, e.g. edrophonium, choline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
- A61K31/4741—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having oxygen as a ring hetero atom, e.g. tubocuraran derivatives, noscapine, bicuculline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/66—Papaveraceae (Poppy family), e.g. bloodroot
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
- A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/14—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/22—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains four or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/564—Three-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/553—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom having one nitrogen atom as the only ring hetero atom
- C07F9/576—Six-membered rings
- C07F9/59—Hydrogenated pyridine rings
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Mycology (AREA)
- Physical Education & Sports Medicine (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Botany (AREA)
- Biotechnology (AREA)
- Alternative & Traditional Medicine (AREA)
- Rheumatology (AREA)
- Immunology (AREA)
- Pulmonology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Diabetes (AREA)
- Toxicology (AREA)
- Dermatology (AREA)
Abstract
La presente se refiere a productos de la reacción alcaloide obtenible en un procedimiento en el que los alcaloides reaccionan con un agente de alquilación, preferiblemente tiotepa, tras lo cual el agente de alquilación no reactivo y otros compuestos solubles en agua se eliminan de la mezcla de reacción lavando con agua o un disolvente acuoso adecuado, tras lo cual la mezcla de reacción se somete a un tratamiento de ácido fuerte, preferiblemente cloruro de hidrógeno (HCl), para precipitar una sal soluble en agua de los productos de reacción. Los productos de reacción precipitados comprenden al menos un derivado alcaloide cuaternario y son adecuados como medicamentos para aplicación profiláctica o terapéutica, particularmente en el tratamiento de disfunciones inmunológicas o metabólicas y cáncer. Reivindicación 9: Un derivado de quelidonina, en el que la quelidonina que aparece naturalmente está presente en una forma cuaternaria según la fórmula (1), en la que como cuarto ligando R1 en el hidrógeno cuaternario está presente un hidrógeno o un residuo metilo o etilo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP03006015A EP1459753A1 (en) | 2003-03-18 | 2003-03-18 | Quaternary chelidonine and alkaloid derivatives, process for their preparation and their use in the manufacture of medicaments |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR043629A1 true AR043629A1 (es) | 2005-08-03 |
Family
ID=32798820
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP040100877A AR043629A1 (es) | 2003-03-18 | 2004-03-17 | Derivados cuaternarios de quelidonina |
Country Status (36)
| Country | Link |
|---|---|
| US (1) | US7795434B2 (es) |
| EP (2) | EP1459753A1 (es) |
| JP (1) | JP5303719B2 (es) |
| KR (1) | KR101020680B1 (es) |
| CN (1) | CN1532198A (es) |
| AR (1) | AR043629A1 (es) |
| AT (1) | ATE469651T1 (es) |
| AU (1) | AU2004222661B2 (es) |
| BR (1) | BRPI0408386A (es) |
| CA (1) | CA2517769C (es) |
| CL (2) | CL2004000552A1 (es) |
| CY (1) | CY1112598T1 (es) |
| DE (1) | DE602004027496D1 (es) |
| DK (1) | DK1644012T3 (es) |
| EA (1) | EA009049B1 (es) |
| ES (1) | ES2346216T3 (es) |
| GE (1) | GEP20084501B (es) |
| GT (1) | GT200400046A (es) |
| HR (1) | HRP20050987B1 (es) |
| IL (1) | IL170505A (es) |
| MA (1) | MA27833A1 (es) |
| MX (1) | MXPA05009919A (es) |
| MY (1) | MY141779A (es) |
| NO (1) | NO333672B1 (es) |
| NZ (1) | NZ542151A (es) |
| PA (1) | PA8598201A1 (es) |
| PE (1) | PE20050351A1 (es) |
| PL (1) | PL1644012T3 (es) |
| PT (1) | PT1644012E (es) |
| SG (1) | SG158748A1 (es) |
| SI (1) | SI1644012T1 (es) |
| TN (1) | TNSN05230A1 (es) |
| TW (1) | TWI347939B (es) |
| UA (1) | UA89353C2 (es) |
| WO (1) | WO2004082698A1 (es) |
| ZA (1) | ZA200507020B (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ITMI20080284A1 (it) * | 2008-02-22 | 2009-08-23 | Indena Spa | Agenti antitumorali a struttura benzofenantridinica e formulazioni che li contengono |
| US8835506B2 (en) | 2008-06-05 | 2014-09-16 | Stc.Unm | Methods and related compositions for the treatment of cancer |
| CN102552264A (zh) * | 2012-02-28 | 2012-07-11 | 苏州大学 | 血根碱在制备电离辐射防护剂中的应用 |
| JP2022552566A (ja) * | 2019-10-17 | 2022-12-16 | チェンドゥ アンタイキャンサー バイオサイエンス リミテッド | ベンゾフェナントリジンアルカロイド及びその使用方法 |
| CN115518069B (zh) * | 2021-05-13 | 2023-11-03 | 山东大学 | 六氢苯并菲啶类生物碱在保护多巴胺神经元中的应用 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SU368254A1 (ru) | 1969-06-16 | 1973-01-26 | А. И. Потопальский , В. М. Новицкий Львовский государственный медицинский институт | Способ получения соединений тиофосфамида с алкалоидами чистотела большого |
| US3865830A (en) * | 1969-06-16 | 1975-02-11 | Nikolai Mikhailovich Turkevich | Thiophosphamide derivatives of isoquinoline alkaloids, method of producing and application thereof |
| AT354644B (de) | 1975-12-19 | 1980-01-25 | Nowicky Wassili | Verfahren zur herstellung von neuen salzen von alkaloidderivaten von thiophosphorsaeure |
| AT377988B (de) | 1976-06-28 | 1985-05-28 | Nowicky Wassili | Verfahren zur herstellung von neuen phosphorderivaten von alkaloiden |
| DE3128018A1 (de) | 1981-07-13 | 1983-04-07 | Wassyl 1060 Wien Nowicky | "verfahren zum diagnostizieren und fuer die therapeutische behandlung von tumoren und/oder infektioesen krankheiten verschiedenster art unter praeparativem einsatz von alkaloid-verbindungen bzw. deren salze" |
| US4970212A (en) | 1982-05-18 | 1990-11-13 | Nowicky Wassili | Method of treating human illnesses which compromise the ability to mount an effective immunological response |
| AT407833B (de) * | 1995-06-01 | 2001-06-25 | Nowicky Wassyl Dr | Mittel zur behandlung von strahlenschäden |
| AT408719B (de) | 2000-03-22 | 2002-02-25 | Nowicky Wassili | Mittel zur behandlung von hepatitis c |
| CH695417A5 (de) | 2001-11-15 | 2006-05-15 | Ddr Wassyl Nowicky Dipl Ing | Verfahren zur Umsetzung von Alkaloiden. |
-
2003
- 2003-03-18 EP EP03006015A patent/EP1459753A1/en not_active Withdrawn
- 2003-06-19 CN CNA031373550A patent/CN1532198A/zh active Pending
-
2004
- 2004-03-12 GE GEAP20048963A patent/GEP20084501B/en unknown
- 2004-03-12 CA CA2517769A patent/CA2517769C/en not_active Expired - Fee Related
- 2004-03-12 DK DK04719983.1T patent/DK1644012T3/da active
- 2004-03-12 US US10/549,433 patent/US7795434B2/en not_active Expired - Fee Related
- 2004-03-12 EP EP04719983A patent/EP1644012B1/en not_active Expired - Lifetime
- 2004-03-12 PT PT04719983T patent/PT1644012E/pt unknown
- 2004-03-12 BR BRPI0408386-5A patent/BRPI0408386A/pt not_active IP Right Cessation
- 2004-03-12 DE DE602004027496T patent/DE602004027496D1/de not_active Expired - Lifetime
- 2004-03-12 MX MXPA05009919A patent/MXPA05009919A/es active IP Right Grant
- 2004-03-12 AU AU2004222661A patent/AU2004222661B2/en not_active Ceased
- 2004-03-12 AT AT04719983T patent/ATE469651T1/de active
- 2004-03-12 ZA ZA200507020A patent/ZA200507020B/en unknown
- 2004-03-12 WO PCT/EP2004/002637 patent/WO2004082698A1/en active Search and Examination
- 2004-03-12 SI SI200431489T patent/SI1644012T1/sl unknown
- 2004-03-12 EA EA200501473A patent/EA009049B1/ru not_active IP Right Cessation
- 2004-03-12 JP JP2006504683A patent/JP5303719B2/ja not_active Expired - Fee Related
- 2004-03-12 ES ES04719983T patent/ES2346216T3/es not_active Expired - Lifetime
- 2004-03-12 SG SG200706589-9A patent/SG158748A1/en unknown
- 2004-03-12 PL PL04719983T patent/PL1644012T3/pl unknown
- 2004-03-12 NZ NZ542151A patent/NZ542151A/en not_active IP Right Cessation
- 2004-03-12 KR KR1020057017086A patent/KR101020680B1/ko not_active IP Right Cessation
- 2004-03-16 MY MYPI20040919A patent/MY141779A/en unknown
- 2004-03-17 AR ARP040100877A patent/AR043629A1/es not_active Application Discontinuation
- 2004-03-17 CL CL200400552A patent/CL2004000552A1/es unknown
- 2004-03-17 PE PE2004000281A patent/PE20050351A1/es not_active Application Discontinuation
- 2004-03-18 TW TW093107196A patent/TWI347939B/zh not_active IP Right Cessation
- 2004-03-18 GT GT200400046A patent/GT200400046A/es unknown
- 2004-03-18 PA PA20048598201A patent/PA8598201A1/es unknown
- 2004-12-03 UA UAA200509763A patent/UA89353C2/uk unknown
-
2005
- 2005-08-25 IL IL170505A patent/IL170505A/en not_active IP Right Cessation
- 2005-09-06 NO NO20054130A patent/NO333672B1/no not_active IP Right Cessation
- 2005-09-16 TN TNP2005000230A patent/TNSN05230A1/en unknown
- 2005-10-17 MA MA28556A patent/MA27833A1/fr unknown
- 2005-12-08 HR HRP20050987AA patent/HRP20050987B1/hr not_active IP Right Cessation
-
2008
- 2008-08-08 CL CL2008002345A patent/CL2008002345A1/es unknown
-
2010
- 2010-08-20 CY CY20101100773T patent/CY1112598T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI106126B (fi) | Menetelmä farmaseuttisten 6-typpisubstituoitujen 4,5-epoksimorfinaanijohdannaisten valmistamiseksi | |
| JP6730922B2 (ja) | 核内輸送調節因子およびその使用 | |
| ES2569655T3 (es) | Procedimientos para la producción de compuestos de (+)-'nal' morfinano | |
| EP2877473B1 (en) | Process for improved opioid synthesis | |
| EP2872516B1 (en) | Process for improved opioid synthesis | |
| CA2670303A1 (en) | (s)-n-stereoisomers of 7,8-saturated-4,5-epoxy-morphinanium analogs | |
| JP2001506600A (ja) | α―２アドレナリン受容体作動薬として有用なグアニジニル複素環式化合物 | |
| AR063415A1 (es) | Hidratos de clorhidrato de erlotinib para el tratamiento del cancer | |
| PT87294B (pt) | Processo para a preparacao de 17 beta-(ciclopropilamino)-androsta-5-eno-3 beta-ol e de compostos relacionados com accao inibidora da c17-20-liase e de composicoes farmaceuticas que os contem | |
| AR043629A1 (es) | Derivados cuaternarios de quelidonina | |
| CA2268968A1 (en) | Iminochlorin aspartic acid derivatives | |
| ES2560537T5 (es) | Procesos para aumentar el rendimiento de la hidrólisis del grupo 3-O-metilo y 17-N-nitrilo en la preparación de derivados alcaloides opiáceos | |
| ES2197001B1 (es) | Procedimiento de obtencion de un compuesto farmaceuticamente activo. | |
| EA022266B1 (ru) | Способ получения налтрексона | |
| RU2412187C1 (ru) | СОЛИ 9-(2-МОРФОЛИНОЭТИЛ)-2-(4-ФТОРФЕНИЛ)ИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА И СОЛИ 9-АМИНОЭТИЛЗАМЕЩЕННЫХ 2-(4-ФТОРФЕНИЛ)ИМИДАЗО[1,2-a]БЕНЗИМИДАЗОЛА, ПРОЯВЛЯЮЩИЕ ОБЕЗБОЛИВАЮЩЕЕ ДЕЙСТВИЕ | |
| CA2954600A1 (en) | Reduction of alpha, beta-unsaturated ketone levels in morphinan derivative compositions | |
| WO2013164383A1 (en) | Method for the manufacturing of naltrexone | |
| WO2016086022A2 (en) | Heteroaromatic imidazolyl compounds and methods for treating cancer | |
| AR074151A1 (es) | Un derivado de benzoilbencenoacetamida, proceso de preparacion del mismo, forma polimorfica b de dicho compuesto, proceso de obtencion de dicha forma polimorfica b y su uso | |
| JP3117251B2 (ja) | １４−Ｏ−ｐ−クロロベンゾイルアコニンおよび鎮痛・抗炎症剤 | |
| EP3890742A1 (en) | Prodrugs of anti-cancer and anti-autoimmune diseases therapeutic agents, and methods of making and use thereof | |
| JO2648B1 (en) | Derivatives of quaternary sheldonin | |
| TH103168B (th) | อนุพันธ์ควอเทอร์นารีคีลิโดนีน | |
| ES2462756T3 (es) | Procedimientos de síntesis de alcaloides opiáceos con formación reducida de impurezas | |
| WO2008065891A1 (fr) | Médicament de protection contre le rayonnement contenant un dérivé d'ester de composé tocophérol ou tocotriénol comme ingrédient actif |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC | Refusal |